FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to otolaryngology, and may be used for treating tinnitus in a person in need thereof. That is ensured by introducing a therapeutically effective dose of a 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt. The therapeutically effective dose of neramexane is introduced daily for a first period making at least three months and followed by a second period making at least one month. The second period involves introducing neramexane in a dose making 0-75% of the therapeutically effective dose provided when neramexane is not introduced during the second period, the treatment of the first period is repeated after the second period.
EFFECT: group of inventions provides clinical effectiveness in treating and preventing tinnitus, as well as a need of maintenance therapy.
24 cl, 1 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NERAMEXANE TITRATION KIT AND USING IT IN TREATING INTERNAL EAR DISORDERS | 2008 |
|
RU2459618C2 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATING COCHLEAR TINNITUS | 2008 |
|
RU2438658C2 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATING AND PREVENTING HEARING LOSS | 2008 |
|
RU2452476C2 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATMENT OF INFLAMMATORY SKIN DISEASES | 2009 |
|
RU2481828C2 |
| NEW COMBINATIONS OF NERAMEXANE FOR TREATING NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2432161C1 |
| MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
| METHOD OF TREATING SKIN INFECTION BY ADMINISTERING ANTAGONIST IL-4R | 2015 |
|
RU2704999C2 |
| DERIVATIVES OF 1-AMINO-ALKYLCYCLOHEXANE FOR TREATMENT OF DISEASES, MEDIATED BY MAST CELLS | 2009 |
|
RU2484813C2 |
| METHODS OF TREATING DISEASES ASSOCIATED WITH S1P1 RECEPTOR | 2021 |
|
RU2821032C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DGLA, AND USE THEREOF | 2015 |
|
RU2714323C2 |
